In the history of human medicine, few technologies have been as laden with extreme survival hopes while simultaneously surrounded by such intense narratives as the artificial heart.
It is not a microchip, not a vaccine, but a mechanical heart attempting to replace the human heartbeat. Every pulsation is a matter of life and death; every promotion is a matter of trust.
China has 13.7 million heart failure patients, a rigorous figure given by the European Journal of Heart Failure in 2019, which is undisputed. But when this number is repeatedly placed in investor roadshows, official propaganda, and media headlines, and tightly bound with "domestic total artificial heart," "lifetime replacement," and "overtaking on a curve," we have reason to pause and ask: Is this scientific hope, or a narrative woven together by capital and nationalism?
Global Finance Media (GFM)'s Financial Investigation column chose the artificial heart as its first major special topic not because it is popular, but because it is dangerous. The danger lies in the fact that when life becomes the most expensive chip, any exaggeration, any silence, any unverified optimism can translate into real death.
Over the past six years, we have seen:
- Billions of RMB flowing rapidly over the words "Domestic Artificial Heart"
- Regulatory documents stating "bridge-to-transplant only," while marketing materials claim "lifetime replacement"
- 30-day mortality rates after right heart failure written into internal medical records but never appearing in any public clinical data
- SynCardia, the only FDA-approved Total Artificial Heart (TAH) globally, has been implanted in nearly 2,000 cases, while China has yet to have a single case of a true TAH approved for permanent implantation
These are not isolated incidents, but a systemic problem: when scientific progress, regulatory pace, capital cycles, and national narratives are misaligned, the most vulnerable are always the patients.
Therefore, we are launching this seven-part investigation report, attempting to piece together scattered fragments into a complete picture:
Part 1
Part 2
Part 3
Comparative Investigation of Global Artificial Hearts
Part 4
Analysis of the Current State of Artificial Hearts in China
Part 5
Part 6
The Shared Lie of Chinese LVAD Companies: Blowing up an Assist Pump into an 'Artificial Heart'?
Part 7
We will not replace evidence with emotion, nor cover up scientific facts with nationalistic opposition. We do only one thing: place original documents, clinical data, regulatory records, investment terms, and patient outcomes on the same plane, and let the readers judge for themselves.
GFM's mission has never been to create opposition, but to rebuild trust. In an era where evidence can be selectively presented and silence can be interpreted as tacit approval, the only weapon left for the media is complete, verifiable, and tamper-proof facts.
If we don't ask, patients will continue to make life-and-death decisions based on incomplete information; If we don't speak, capital will continue to make multi-billion dollar bets based on incomplete due diligence; If we don't turn on the lights, these 13.7 million patients will continue to grope in the dark.
This is the reason for the existence of GFM's Financial Investigation column.
This is our promise to every person still waiting for a heartbeat.
The investigation begins.
The truth waits for no one, and life certainly does not.
Please send your thoughts to the encrypted GFM email: newsroom@gfm.news
Global Finance Media "Financial Investigation" Column Investigation Team